{
    "clinical_study": {
        "@rank": "141369", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Fibrin sealant only."
            }, 
            {
                "arm_group_label": "Cethrin (BA-210) - 3 mg Dose", 
                "arm_group_type": "Experimental", 
                "description": "3 mg of Cethrin in a fibrin sealant."
            }, 
            {
                "arm_group_label": "Cethrin (BA-210) - 6 mg Dose", 
                "arm_group_type": "Experimental", 
                "description": "6 mg of Cethrin in a fibrin sealant."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, randomized, double-blind, placebo-controlled Phase IIb study designed\n      to evaluate the efficacy and safety of Cethrin as a treatment for acute cervical spinal cord\n      injury. During the trial, 3 mg and 6 mg doses of Cethrin will be compared with placebo."
        }, 
        "brief_title": "Cethrin in Acute Cervical Spinal Cord Injury", 
        "condition": "Spinal Cord Injury", 
        "condition_browse": {
            "mesh_term": [
                "Spinal Cord Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females, ages 18-62, inclusive\n\n          -  Acute cervical spinal cord injury at a neurological level of C4 or C5\n\n          -  AIS Grade A or B\n\n          -  Scheduled to undergo decompression/stabilization surgery within five days of injury\n\n          -  Written or verbal consent from patient or legally authorized representative that\n             patient is able and willing to comply with the study protocol, including follow-up\n             visits\n\n        Exclusion Criteria:\n\n          -  Participation in any other clinical trial for acute SCI, including previous Cethrin\n             trial\n\n          -  Inability to receive study medication within five days of injury\n\n          -  Acute SCI from gunshot or penetrating/stab wound, complete spinal cord transection,\n             or multifocal SCI\n\n          -  Detectable hemorrhage on MRI/CT scan\n\n          -  Females who are breastfeeding or have a positive serum pregnancy test\n\n          -  Body mass index (BMI) of \u226540 kg/m2 at screening\n\n          -  History of an adverse reaction to a fibrin sealant or its human or bovine components\n\n          -  Use of intravenous heparin in previous 48 hours\n\n          -  Use of thrombolytics and/or aspirin-containing products in previous 24 hours\n\n          -  Hemophilia or other bleeding abnormality (platelet level lower than 100 X 109/L,\n             activated partial thromboplastin time or international normalized ratio higher than\n             the upper limit of normal, or baseline hematocrit lower than 0.25)\n\n          -  Unconsciousness or other mental impairment that precludes reliable ASIA examination\n\n          -  Clinically significant neurological, cardiac, hepatic, or renal disease\n\n          -  Any medical or other condition that, in the judgment of the investigator, would make\n             participation in the study unsafe or unreasonably complicate follow-up/interpretation\n             of study outcome data"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "62 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 31, 2014", 
        "id_info": {
            "nct_id": "NCT02053883", 
            "org_study_id": "BA-210-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cethrin (BA-210) - 3 mg Dose", 
                    "Cethrin (BA-210) - 6 mg Dose"
                ], 
                "description": "3 mg or 6 mg of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.", 
                "intervention_name": "Cethrin (BA-210)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fibrin Tissue Adhesive"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "SCI", 
            "spinal cord injury", 
            "biologic drug", 
            "rho", 
            "paralysis", 
            "paraplegia", 
            "tetraplegia", 
            "quadriplegia", 
            "trauma", 
            "central nervous system", 
            "fibrin sealant", 
            "neurosurgery", 
            "cervical", 
            "regeneration", 
            "neurotrauma"
        ], 
        "lastchanged_date": "February 1, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Cethrin in Subjects With Acute Cervical Spinal Cord Injury", 
        "overall_contact": {
            "email": "lisa.bond@bioaxonebio.com", 
            "last_name": "Lisa Bond, PhD"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "American Spinal Injury Association (ASIA) Upper Extremity Motor Score Recovery", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02053883"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "ASIA Total Motor Score Recovery", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Months"
            }, 
            {
                "measure": "ASIA Impairment Scale (AIS) Grade Recovery", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Months"
            }, 
            {
                "measure": "Motor Neurological Level Recovery", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Months"
            }, 
            {
                "measure": "ASIA Sensory Score Recovery", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Months"
            }, 
            {
                "measure": "Spinal Cord Independence Measure (SCIM) III (Total Score, Self-Care Subscore)", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }, 
            {
                "measure": "Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP)", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }, 
            {
                "measure": "Incidence of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "0-6 Months"
            }
        ], 
        "source": "BioAxone BioSciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioAxone BioSciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}